A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety studyLipsic, E., van der Meer, P., Voors, A. A., Westenbrink, B. D., van den Heuvel, A. F. M., de Boer, H. C., van Zonneveld, A. J., Schoemaker, R. G., van Gilst, W. H., Zijlstra, F. & van Veldhuisen, D. J., Apr-2006, In : Cardiovascular Drugs and Therapy. 20, 2, p. 135-141 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
Aims: Besides stimulating hematopoiesis, erythro-poietin (EPO) protects against experimental ischemic injury in the heart. The present study evaluated the safety and tolerability of EPO treatment in non-anemic patients with acute myocardial infarction (MI).
Methods and Results: In this single-center, investigator-initiated, prospective study, patients with a first acute MI were randomized to one bolus of 300 mu g darbepoetin alfa or no additional medication before primary coronary intervention. Twenty-two patients (mean age 59 +/- 2 years) were included. In the darbepoetin group, serum EPO-levels increased to 130-270 times that of controls, within the first 24 h. After darbepoetin administration, only small and nonsignificant changes in hematocrit levels were observed, while endothelial progenitor cells (EPCs, CD34+/CD45-) were increased at 72 h (2.8 vs. 1.0 cells/mu l in control group,p <0.01). No adverse events were recorded during the 30-day follow-up. After 4 months, left ventricular ejection fraction was similar in the two groups (52 +/- 3% in darbepoetin vs. 48 +/- 5% in control group, p = NS).
Conclusions: Intravenous single high-dose darbepoetin alfa in acute MI is both safe and well tolerated. Darbepoetin treatment after MI stimulates EPCs mobilization. The results of this first pilot study support a larger scale clinical trial to establish efficacy of EPO administration in patients after acute MI.
|Number of pages||7|
|Journal||Cardiovascular Drugs and Therapy|
|Publication status||Published - Apr-2006|
- acute myocardial infarction, erythropoietin, endothelial progenitor cells, ENDOTHELIAL PROGENITOR CELLS, RECOMBINANT-HUMAN-ERYTHROPOIETIN, LEFT-VENTRICULAR FUNCTION, CHRONIC HEART-FAILURE, HEMOGLOBIN LEVELS, SIZE, ANEMIA, RATS, HEMODIALYSIS, MORTALITY